Clinical trials: Inadequate Response
Atopic Dermatitis, Atopic Dermatitis, Unspecified
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
- Trial name
- NCT06899204
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pfizer
Nasopharyngeal Carcinoma
CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy
This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not…
- Trial name
- NCT07399158
- Volunteers
- 223 people
- Sponsor
- Fujian Cancer Hospital
Rheumatoid Arthritis
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching…
- Trial name
- NCT01668641
- Testing
- GLPG0634
- Where
- 19 sites in Hungary, Moldova and 2 more
- Volunteers
- 91 people
- Sponsor
- Lakefront Biotherapeutics NV
Primary Biliary Cholangitis
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
The purposes of this study are to evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of…
- Trial name
- NCT04620733
- Testing
- Seladelpar 10 mg, Seladelpar 5 mg
- Where
- 134 sites in United States, Argentina and 24 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Pain, Postoperative, Analgesic Requirement
Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy
Laparoscopic Cholecystectomy is the treatment of choice for patients with symptomatic gall stones. For pain relief following laparoscopic cholecystectomy both intraperitoneal and intravenous administration of lignocaine has been…
- Conditions
- Pain, Postoperative, Analgesic Requirement, Stress Response, Return of Bowel Activity
- Trial name
- NCT01717222
- Testing
- Intraperitoneal Lignocaine, Intravenous Lignocaine
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Acute Treatment of Migraine
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult…
- Trial name
- NCT07685769
- Testing
- Rimegepant 75 mg ODT
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)
The purpose of this study is to determine if CH-4051 is a safe and effective treatment for rheumatoid arthritis.
- Trial name
- MOTION (NCT01116141)
- Testing
- CH-4051, Methotrexate (MTX), Folic Acid
- Volunteers
- 250 people
- Sponsor
- Chelsea Therapeutics
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
This multicenter, randomized, double-blind, active-controlled study aims to evaluate the efficacy and safety of picankibart in Chinese patients with plaque psoriasis who demonstrated inadequate responses to interleukin-17 (IL-17)…
- Trial name
- NCT06945107
- Testing
- Picankibart, Secukinumab, Ixekizumab
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Primary Immune Thrombocytopenia
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with…
- Trial name
- VAYHIT2 (NCT05653219)
- Testing
- Ianalumab, Eltrombopag
- Where
- 74 sites in United States, Argentina and 22 more
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate.
- Trial name
- FLEX M (NCT01198002)
- Testing
- LY2127399, Methotrexate
- Where
- 234 sites in United States, Argentina and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The purpose of this study is to investigate the efficacy and safety of Hydroxytriptolide(LTS) in active rheumatoid arthritis patients with an inadequate response to methotrexate.
- Trial name
- T8 (NCT02202395)
- Testing
- LTS 0.25mg, LTS 0.5mg, LTS 1.0mg
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies.
- Trial name
- NCT00462345
- Testing
- rituximab, Methotrexate, Corticosteroid or NSAID
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients.
- Trial name
- NCT05751967
- Testing
- Fenofibrate Combined With Ursodeoxycholic Acid
- Where
- 7 sites in China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not…
- Trial name
- OSKIRA - 2 (NCT01197534)
- Testing
- fostamatinib
- Where
- 149 sites in United States, Canada and 14 more
- Volunteers
- 913 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria (CSU)
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
The goal of this clinical trial is to learn if different doses of TLL-018 works to treat in moderate-to-severe chronic spontaneous urticaria (CSU) participants . It will also learn about the safety of TLL-018.
- Trial name
- NCT07764003
- Testing
- TLL-018 tablets
- Volunteers
- 140 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Rheumatoid Arthritis
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX…
- Trial name
- 986 (NCT01999192)
- Testing
- Tregalizumab
- Where
- 84 sites in United States, Bulgaria and 12 more
- Volunteers
- 321 people
- Sponsor
- Biotest